Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: Clinicopathological study of five patients

British Journal of Dermatology

Volumn 153, Issue 2, 2005, Pages 417-423

  Vila, Antonia Teresa ^a,c   Puig, L ^a   Fernandez Figueras M T ^b   Laiz, A M ^a   Vidal, D ^a   Alomar, A ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c HOSPITAL SON LLÀTZER   (Spain)

Author keywords

Adverse cutaneous reaction; Anakinra; Interleukin 1 receptor antagonist; Rheumatoid arthritis; Toxicoderma

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; CD45 ANTIGEN; CD45RO ANTIGEN; CD68 ANTIGEN; EOSIN; HEMATOXYLIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; CELL POPULATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; GIEMSA STAIN; HISTOPATHOLOGY; HUMAN; IMMUNOREACTIVITY; INJECTION SITE REACTION; LICHENOID; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MAST CELL; MONONUCLEAR CELL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SKIN BIOPSY; SKIN EDEMA; SKIN MANIFESTATION;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ERUPTIONS; DRUG THERAPY, COMBINATION; EDEMA; EOSINOPHILS; ERYTHEMA; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MACROPHAGES; MIDDLE AGED; RECOMBINANT PROTEINS; SIALOGLYCOPROTEINS;

EID: 24144453133     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06635.x     Document Type: Article

References (27)

1. Conti P. Interleukin-1 (IL-1) and interleukin-1 receptor antagonist (IL-1ra). Ann Med Interne (Paris) 1991; 142:521-5.
2. Elliott MJ, Maini RN. Anti-cytokine therapy in rheumatoid arthritis. Baillieres Clin Rheumatol 1995; 9:633-52.
3. Grassi W, De Angelis R, Lamanna G, Cervini C. The clinical features of rheumatoid arthritis. Eur J Radiol 1998; 27:S18-24.
4. Eastgate JA, Symons JA, Wood NC et al. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 1988; ii:706-9.
5. Dinarello CA. Interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 1998; 16:457-99.
6. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998; 16:27-55.
7. McIntyre KW, Stepan GJ, Kolinsky KD et al. Inhibition of interleukin-1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody. J Exp Med 1991; 173:931-9.
8. Firestein GS, Boyle DL, Yu C et al. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum 1994; 37:644-52.
9. Cohen S, Hurd E, Cush J et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate. Arthritis Rheum 2002; 46:614-24.
10. Nuki G, Bresnihan B, Bear MB, McCabe D. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis. Arthritis Rheum 2002; 46:2838-46.
11. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004; 350:2167-79.
12. Burls A, Jobanputra P. The trials of anakinra. Lancet 2004; 364:827-8.
13. Wendling D, Jorgensen C. Treatment of rheumatoid arthritis by interleukin-1 receptor antagonist. Rev Med Interne 2002; 23:1006-11.
14. Langer HE, Missler-Karger B. Kineret: efficacy and safety in daily clinical practice: an interim analysis of the Kineret response assessment initiative (kreative) protocol. Int J Clin Pharmacol Res 2003; 23:119-28.
15. Fleischmann RM, Schechtman J, Bennett R et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48:927-34.
16. Riente L. Sicurezza e tolerabilità dell'antagonista del recettore dell'interleuchina-1 nel trattamento dell'artrite reumatoide. Reumatismo 2004; 56:74-9.
17. Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis: a randomised, controlled trial. Ann Intern Med 1999; 130:478-86.
18. Horn TD, Burke PJ, Karp JE, Hood AF. Intravenous administration of recombinant human granulocyte-macrophage colony-stimulating factor causes a cutaneous eruption. Arch Dermatol 1991; 127:49-52.
19. Scott GA. Report of three cases of cutaneous reactions to granulocyte macrophage-colony-stimulating factor and a review of the literature. Am J Dermatopathol 1995; 17:107-14.
20. Glass LF, Fotopoulos T, Messina JL. A generalized cutaneous reaction induced by granulocyte colony-stimulating factor. J Am Acad Dermatol 1996; 34:455-9.
21. Alvarez-Ruiz S, Peñas PF, Fernández-Herrera J et al. A maculopapular eruption with enlarged macrophages in eight patients receiving G-CSF or GM-CSF. J Eur Acad Dermatol Venereol 2004; 18:310-13.
22. Valks R, Vargas E, Muñoz E et al. Dermal infiltrate of enlarged macrophages in patients receiving chemotherapy. J Cutan Pathol 1998; 25:259-64.
23. Mehregan DR, Fransway AF, Edmonson JH, Leiferman KM. Cutaneous reactions to granulocyte-monocyte colony-stimulating factor. Arch Dermatol 1992; 128:1055-9.
24. Simon D, Braathen LR, Simon HU. Eosinophils and atopic dermatitis. Allergy 2004; 59:561-70.
25. Elsner J, Kapp A. Regulation and modulation of eosinophil effector functions. Allergy 1999; 54:15-26.
26. Bendele A, Colloton M, Vrkljan M et al. Cutaneous mast cell degranulation in rats receiving injections of recombinant human interleukin-1 receptor antagonist (rhIL-1ra) and/or its vehicle: possible clinical implications. J Lab Clin Med 1995; 125:493-500.
27. Bugarski D, Jovcic G, Kataranovski M et al. Effects of treatment with interleukin-1 receptor antagonist on endogenous interleukin-1 levels in normal and irradiated mice. Physiol Res 2000; 49:355-62.